Abbvie Inc
NYSE:ABBV

Watchlist Manager
Abbvie Inc Logo
Abbvie Inc
NYSE:ABBV
Watchlist
Price: 172.99 USD 0.76% Market Closed
Market Cap: 306B USD
Have any thoughts about
Abbvie Inc?
Write Note

Intrinsic Value

The intrinsic value of one ABBV stock under the Base Case scenario is 153.25 USD. Compared to the current market price of 172.99 USD, Abbvie Inc is Overvalued by 11%.

The Intrinsic Value is calculated as the average of DCF and Relative values:

ABBV Intrinsic Value
153.25 USD
Overvaluation 11%
Intrinsic Value
Price
Worst Case
Base Case
Best Case

Valuation History
Abbvie Inc

Intrinsic Value History
Dive into the past to invest in the future

Uncover deeper insights with the Valuation History. Learn how current stock valuations stack up against historical averages to gauge true investment potential.

Start now and learn if your stock is truly undervalued or overvalued!

Start Valuation
Backtest Conclusion
Very Attractive
Current Valuation
+45%
Avg Valuation
-12%
Worst Valuation
-49%
Best Valuation
+45%

Stock is trading at its lowest valuation over the past 5 years.

Backtest Example
ABBV
Valuation History
HIDDEN
Show
Valuation History Unavailable

Historical valuation for ABBV cannot be conducted due to limitations such as insufficient data or other constraints.

Valuation In Progress...
Valuation In Progress...

Fundamental Analysis

Company Overview
Loading...
Business Segments
Loading...
Economic Moat
Loading...
Earnings Call
Loading...
Management
Loading...
Contacts
Loading...
Bear Theses

With Humira’s patent protection expiring in key markets, AbbVie faces an impending revenue cliff that may be difficult to replace with newer therapies in the short term, potentially straining cash flows and earnings.

AbbVie’s heavy reliance on the immunology franchise means that any pipeline setbacks—especially for Skyrizi or Rinvoq—could undercut management’s guidance for replacing lost Humira sales, exposing the firm to volatility.

The large debt load from recent acquisitions, combined with integration risks from Allergan, may limit AbbVie’s flexibility to pursue additional M&A deals or invest aggressively in R&D, weakening its competitive stance.

Bull Theses

Skyrizi and Rinvoq have shown strong clinical data and commercial traction, signifying AbbVie’s potential to sustain leadership in immunology and mitigate the Humira patent cliff through these next-generation therapies.

The Allergan acquisition diversifies AbbVie’s product portfolio into aesthetics and neuroscience, mitigating overdependence on immunology and providing additional long-term growth and cash flow opportunities.

AbbVie’s robust R&D engine and track record of successful drug development, paired with strategic partnerships, position it to expand its oncology and neuroscience pipelines, potentially unlocking future blockbusters beyond its immunology foundation.

Show More Less
How do you feel about ABBV?
Bearish
Neutral
Bullish
AI Assistant
AI Assistant
Ask me anything about Abbvie Inc

Provide an overview of the primary business activities
of Abbvie Inc.

What unique competitive advantages
does Abbvie Inc hold over its rivals?

What risks and challenges
does Abbvie Inc face in the near future?

Has there been any significant insider trading activity
in Abbvie Inc recently?

Summarize the latest earnings call
of Abbvie Inc.

What significant events have occurred
in Abbvie Inc over the past months?

Is it considered overvalued or undervalued
based on the latest financial data?

Show all valuation multiples
for Abbvie Inc.

Provide P/S
for Abbvie Inc.

Provide P/E
for Abbvie Inc.

Provide P/OCF
for Abbvie Inc.

Provide P/FCFE
for Abbvie Inc.

Provide P/B
for Abbvie Inc.

Provide EV/S
for Abbvie Inc.

Provide EV/GP
for Abbvie Inc.

Provide EV/EBITDA
for Abbvie Inc.

Provide EV/EBIT
for Abbvie Inc.

Provide EV/OCF
for Abbvie Inc.

Provide EV/FCFF
for Abbvie Inc.

Provide EV/IC
for Abbvie Inc.

Show me price targets
for Abbvie Inc made by professional analysts.

What are the Revenue projections
for Abbvie Inc?

How accurate were the past Revenue estimates
for Abbvie Inc?

What are the Net Income projections
for Abbvie Inc?

How accurate were the past Net Income estimates
for Abbvie Inc?

What are the EPS projections
for Abbvie Inc?

How accurate were the past EPS estimates
for Abbvie Inc?

What are the EBIT projections
for Abbvie Inc?

How accurate were the past EBIT estimates
for Abbvie Inc?

Compare the revenue forecasts
for Abbvie Inc with those of its competitors based on recent analyst estimates.

Compare the intrinsic valuations
of Abbvie Inc and its key competitors using the latest financial data.

Compare historical revenue growth rates
of Abbvie Inc against its competitors.

Analyze the profit margins
(gross, operating, and net) of Abbvie Inc compared to its peers.

Compare the P/E ratios
of Abbvie Inc against its peers.

Discuss the investment returns and shareholder value creation
comparing Abbvie Inc with its peers.

Analyze the financial leverage
of Abbvie Inc compared to its main competitors.

Show all profitability ratios
for Abbvie Inc.

Provide ROE
for Abbvie Inc.

Provide ROA
for Abbvie Inc.

Provide ROIC
for Abbvie Inc.

Provide ROCE
for Abbvie Inc.

Provide Gross Margin
for Abbvie Inc.

Provide Operating Margin
for Abbvie Inc.

Provide Net Margin
for Abbvie Inc.

Provide FCF Margin
for Abbvie Inc.

Show all solvency ratios
for Abbvie Inc.

Provide D/E Ratio
for Abbvie Inc.

Provide D/A Ratio
for Abbvie Inc.

Provide Interest Coverage Ratio
for Abbvie Inc.

Provide Altman Z-Score Ratio
for Abbvie Inc.

Provide Quick Ratio
for Abbvie Inc.

Provide Current Ratio
for Abbvie Inc.

Provide Cash Ratio
for Abbvie Inc.

What is the historical Revenue growth
over the last 5 years for Abbvie Inc?

What is the historical Net Income growth
over the last 5 years for Abbvie Inc?

What is the current Free Cash Flow
of Abbvie Inc?

Discuss the annual earnings per share (EPS)
trend over the past five years for Abbvie Inc.

Financials
Annual
Quarterly
TTM
Annual
Quarterly
TTM

Balance Sheet Decomposition
Abbvie Inc

Current Assets 25.6B
Cash & Short-Term Investments 5.6B
Receivables 10.9B
Other Current Assets 9.1B
Non-Current Assets 109.6B
Long-Term Investments 279m
PP&E 5.1B
Intangibles 95B
Other Non-Current Assets 9.1B
Current Liabilities 38.7B
Accounts Payable 31.9B
Other Current Liabilities 6.8B
Non-Current Liabilities 93.1B
Long-Term Debt 60.3B
Other Non-Current Liabilities 32.7B
Efficiency

Free Cash Flow Analysis
Abbvie Inc

Last Value
3-Years Average
FCF Margin
Conversion Rate

Earnings Waterfall
Abbvie Inc

Revenue
56.3B USD
Cost of Revenue
-16.9B USD
Gross Profit
39.4B USD
Operating Expenses
-22.9B USD
Operating Income
16.5B USD
Other Expenses
-12.3B USD
Net Income
4.2B USD
Fundamental Scores

ABBV Profitability Score
Profitability Due Diligence

Abbvie Inc's profitability score is 72/100. The higher the profitability score, the more profitable the company is.

Exceptional 3-Year Average ROE
Positive Free Cash Flow
Positive Gross Profit
Exceptional ROE
72/100
Profitability
Score

Abbvie Inc's profitability score is 72/100. The higher the profitability score, the more profitable the company is.

ABBV Solvency Score
Solvency Due Diligence

Abbvie Inc's solvency score is 27/100. The higher the solvency score, the more solvent the company is.

Long-Term Solvency
Average Altman Z-Score
Short-Term Solvency
Positive Net Debt
27/100
Solvency
Score

Abbvie Inc's solvency score is 27/100. The higher the solvency score, the more solvent the company is.

Wall St
Price Targets

ABBV Price Targets Summary
Abbvie Inc

Wall Street analysts forecast ABBV stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for ABBV is 219.74 USD with a low forecast of 174.73 USD and a high forecast of 263.55 USD.

Lowest
Price Target
174.73 USD
1% Upside
Average
Price Target
219.74 USD
27% Upside
Highest
Price Target
263.55 USD
52% Upside
View Analyst Estimates
View Analyst Estimates

Dividends

Dividend Yield
Lowest
Average
Highest
Dividend Per Share
N/A
Growth 3Y
Growth 5Y
Growth 10Y
Dividend Safety Score
Very
Unsafe
Unsafe
Safe
Very
Safe
0
25
50
75
100
Shareholder Yield

Current shareholder yield for ABBV is .

Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?

Shareholder Yield
Dividend Yield
Lowest
Average
Highest
Buyback Yield
Lowest
Average
Highest
Debt Paydown Yield
Lowest
Average
Highest

Ownership

ABBV Insider Trading
Buy and sell transactions by insiders

ABBV News

Other Videos
What is the Intrinsic Value of one ABBV stock?

The intrinsic value of one ABBV stock under the Base Case scenario is 153.25 USD.

Is ABBV stock undervalued or overvalued?

Compared to the current market price of 172.99 USD, Abbvie Inc is Overvalued by 11%.

Back to Top